NYSE:BMYPharmaceuticals
Bristol Myers Squibb (BMY) Stock May Be 46% Below Fair Value As FDA Approval Lands
Bristol-Myers Squibb stock has delivered a 40.6% 1 year return, while both its Discounted Cash Flow (DCF) intrinsic value estimate and market multiples currently point to the shares trading at a discount to what the business may be worth.
The 40.6% gain over the past year suggests sentiment has improved, yet current valuation signals still indicate the market price may be below intrinsic value.
Recent FDA accelerated approval for ZENBEXUS can support expectations for future cash flows, while...